Bernstein Research has taken a close look at the Sartorius vz share. These are the results.
The US analysis house Bernstein Research has left Sartorius at “underperform” with a price target of 194 euros. The designated successor to company boss Joachim Kreuzburg, Michael Grosse, must shift the narrative for the laboratory and pharmaceutical supplier’s shares from incoming orders to commercialization successes, wrote analyst Delphine Le Louet in a study available on Monday.
Current stock recommendation: The Sartorius vz share is the focus of analysis and evaluation
At 1:05 p.m., the Sartorius vz share slipped 0.3 percent to EUR 211.80 in the XETRA session. As a result, the share still shows room for improvement: 8.40 percent in relation to the set price target. Most recently, 34,469 Sartorius vz shares were traded via XETRA. Since the beginning of 2024, the share price has fallen by 36.3 percent. It is estimated that Sartorius will present its Q4 2024 financial results on January 23, 2025.
NEW YORK (dpa-AFX Analyzer) / editorial team finanzen.net
Publication of the original study: 09.12.2024 / 07:15 / UTC First distribution of the original study: 09.12.2024 / 07:15 / UTC
Note: Information on the obligation to disclose conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenstellenpflicht/ disclosure_duty.html.
Selected leverage products on Sartorius vz.
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Sartorius vz.
The leverage must be between 2 and 20
Advertising
Image sources: T. Schneider / Shutterstock.com